H

Hua Medicine
HKEX:2552

Watchlist Manager
Hua Medicine
HKEX:2552
Watchlist
Price: 1.31 HKD -1.5% Market Closed
Market Cap: 1.3B HKD
Have any thoughts about
Hua Medicine?
Write Note

Hua Medicine
Investor Relations

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.

Show more
Loading
2552
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Li Chen Ph.D.
Founder, CEO & Executive Director
No Bio Available
Mr. Chien Cheng Lin J.D.
Executive VP & Chief Strategy Officer
No Bio Available
Dr. Fuxing Tang Ph.D.
CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA
No Bio Available
Dr. Changhong Li Ph.D.
Chief Scientific Officer
No Bio Available
Mr. Chengde Wang
Head of IR
No Bio Available
Dr. Yi Zhang M.D., Ph.D.
Senior VP of Pharma Development, Chief Medical Officer ? China and Executive Director
No Bio Available
Mr. Ying Xie M.B.A.
VP of Quality Assurance Division & Chief Quality Officer
No Bio Available
Ms. Wing Yan Yuen FCIS, FCS
Company Secretary
No Bio Available

Contacts

Address
SHANGHAI
Shanghai
Hua Medicine, Building 2, Lane 36, Xuelin Road, Pudong New Area
Contacts